Recent developments in the management of choroidal melanoma

Current Opinion in Ophthalmology

Volumn 15, Issue 3, 2004, Pages 244-251

  Shields, Carol L ^a,b   Shields, Jerry A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b WILLS EYE HOSPITAL   (United States)

Author keywords

Cancer; Choroids; Ciliary body; Enucleation; Eye; Intraocular; Iris; Melanoma; Plaque radiotherapy; Treatment; Tumor; Uvea

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; IMMUNOMODULATING AGENT;

CANCER CONTROL; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHOROID MELANOMA; CLINICAL FEATURE; CONSERVATIVE TREATMENT; ENUCLEATION; HUMAN; HYPERTHERMIC THERAPY; LASER COAGULATION; METASTASIS; OPTIC DISK; PATIENT COUNSELING; PERIODIC MEDICAL EXAMINATION; PIGMENTATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SUBRETINAL FLUID; SURVIVAL RATE; SYMPTOM; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR VOLUME;

CHOROID NEOPLASMS; EYE ENUCLEATION; HUMANS; HYPERTHERMIA, INDUCED; LASER COAGULATION; MELANOMA; RADIOTHERAPY;

EID: 2442519348     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.icu.0000120713.35941.e4     Document Type: Review

References (63)

1. Robertson DM: Changing concepts in the management of choroidal melanoma. Am J Ophthalmol 2003, 136:161-170. Choroidal melanoma is a potential deadly tumor. There is a trend toward treatment of smaller choroidal melanomas. The management of choroidal melanoma will be improved if effective systemic therapies can be identified.
2. Shields CL, Shields JA, Gunduz K, et al.: Radiation therapy for uveal malignant melanoma. Ophthal Surg Lasers 1998, 29:397-409.
3. Shields JA, Shields CL: Surgical approach to lamellar sclerouvectomy for posterior uveal melanomas. The 1986 Schoenberg Lecture. Ophthal Surg 1988, 19:774-780.
4. Zimmerman LE, McLean IW: An evaluation of enucleation in the management of uveal melanomas. Am J Ophthalmol 1979, 87:741-760.
5. Zimmerman LE, McLean IW, Foster WD: Does enucleation of the eye containing a malignant melanoma prevent or accelerate the dissemination of tumour cells? Br J Ophthalmol 1978, 62:420-425.
6. Manschot WA, Van Peperzeel HA: Choroidal melanoma-enucleation or observation? A new approach. Arch Ophthalmol 1980, 98:71-77.
7. Seigel D, Myers M, Ferris F, Steinhom SC: Survival rates after enucleation of eyes with malignant melanoma. Am J Ophthalmol 1979, 87:751-765.
8. Straatsma BR, Fine SL, Earle JD: The Collaborative Ocular Melanoma Study Research Group. Enucleation versus plaque irradiation for choroidal melanoma. Ophthalmology 1988, 95:1000-1004.
9. Collaborative Ocular Melanoma Study Group: Trends in size and treatment of recently diagnosed choroidal melanoma, 1987-1997: findings from patients examined at collaborative ocular melanoma study (COMS) centers: COMS report no. 20. Arch Ophthalmol 2003, 121:1156-1162.
10. Shields CL, Cater JC, Shields JA, et al.: Combination of clinical factors predictive of growth of small choroidal melanocytic tumors. Arch Ophthalmol 2000, 118:360-364.
11. Shields C, Shields JA, Kiratli H, et al.: Risk factors for growth and metastasis of small choroidal melanocytic lesions. Ophthalmology 1995, 102:1351-1361.
12. Sumich P, Mitchell P, Wang JJ: Choroidal nevi in a white population: the Blue Mountains Eye Study. Arch Ophthalmol 1998, 116:645-650.
13. Ganley JP, Comstick GW: Benign nevi and malignant melanomas of the choroids. Am J Ophthalmol 1973, 76:19-25.
14. Shields CL, Shields JA: Clinical features of small choroidal melanoma. Curr Opin Ophthalmol 2002, 13:135-141. Factors that differentiate small choroidal melanoma from choroidal nevus can be remembered using the mnemonic TFSOM, indicating To Find Small Ocular Melanoma. The letters in this mnemonic represent T (Thickness >2 mm), F (subretinal Fluid), S (Symptoms), O (Orange pigment), and M (Margin touching optic disc). Choroidal melanocytic tumors that display 0 factors have 3% chance for growth at 5 years and most likely represent choroidal nevi. Tumors that display one factor have a 38% chance for growth, and those with two or more factors show growth in more than 50% of cases at 5 years.
15. Straatsma BR, Diener-West M, Caldwell R, et al.: Collaborative Ocular Melanoma Study Group. Mortality after deferral of treatment or no treatment for choroidal melanoma. Am J Ophthalmol 2003, 136:47-54. Based on 45 patients with medium-sized melanoma who refused treatment. Greater mortality and higher risk of death for natural history study patients are probative but not conclusive evidence of a beneficial, life-extending effect of medium melanoma treatment.
16. Foulds WS, Damato BE: Low energy long-exposure laser therapy in the management of choroidal melanoma. Graefes Arch Clin Exp Ophthalmol 1986, 224:26-31.
17. Shields JA, Glazer LC, Mieler WF, Shields CL: Comparison of xenon arc and argon laser photocoagulation in the treatment of choroidal melanomas. Am J Ophthalmol 1990, 109;647-655.
18. Barbazetto IA, Lee TC, Rollins IS, et al.: Treatment of choroidal melanoma using photodynamic therapy. Am J Ophthalmol 2003, 135;898-899.
19. Oosterhuis JA, Journee-de Korver HG, Kakebeeke-Kemme HM, et al.: Transpupillary thermotherapy in choroidal melanomas. Arch Ophthalmol 1995, 113:315-321.
20. Shields CL, Shields JA, Cater J, et al.: Transpupillary thermotherapy for choroidal melanoma. Tumor control and visual outcome in 100 consecutive cases. Ophthalmology 1998, 105:581-590.
21. Shields CL, Shields JA, DePotter P, et al.: Transpupillary thermotherapy in the management of choroidal melanoma. Ophthalmology 1996, 103:1642-1650.
22. Shields CL, Shields JA, Perez N, et al.: Primary transpupillary thermotherapy for small choroidal melanoma in 256 consecutive cases: outcomes and limitations. Ophthalmology 2002, 109:225-234. Transpupillary thermotherapy is an effective treatment for certain small choroidal melanomas. Appropriate tumor selection is critical to successful treatment. Patients with tumors abutting or overhanging the optic disc or those requiring more than three sessions for tumor control are more likely to develop ultimate tumor recurrence. Transpupillary thermotherapy can cause damaging effects to the retina, leading to visual loss shortly after treatment.
23. Singh AD, Eagle RC Jr, Shields CL, et al.: Enucleation following transpupillary thermotherapy of choroidal melanoma: clinicopathologic correlations. Arch Ophthalmol 2003, 121:397-400.
24. Zaldivar RA, Aaberg TM, Sternberg P Jr, et al.: Clinicopathologic findings in choroidal melanomas after failed transpupillary thermotherapy. Am J Ophthalmol 2003, 135:657-663.
25. Shields CL, Cater J, Shields JA, et al.: Combined plaque radiotherapy and transpupillary thermotherapy for choroidal melanoma in 270 consecutive patients. Arch Ophthalmol 2002, 120:933-940.
26. Rem AI, Oosterhuis JA, Journee-de Korver HG, et al.: Transscleral thermotherapy: short- and long-term effects of transscleral conductive heating in rabbit eyes. Arch Ophthalmol 2003, 121:510-516.
27. Collaborative Ocular Melanoma Study (COMS) [Randomized trial of I-125 brachytherapy for choroidal melanoma]: III. Initial mortality findings. COMS report no 16. Ophthalmology 2001, 108:348-366.
28. The Collaborative Ocular Melanoma Study Group: The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS report no. 18. Arch Ophthalmol 2001, 119:969-982. Mortality rates after plaque brachytherapy with radioactive iodine 125 did not differ from mortality rates after enucleation for up to 12 years after treatment of patients with choroidal melanoma.
29. DePotter P, Shields CL, Shields JA, et al.: The impact of enucleation versus plaque radiotherapy in the management of juxtapapillary choroidal melanoma on patient survival. Br J Ophthalmol 1994, 78:109-114.
30. Gunduz K, Shields CL, Shields JA, et al.: Plaque radiotherapy for management of ciliary body and choroidal melanoma with extrascleral extension. Am J Ophthalmol 2000, 130:97-102.
31. Gunduz K, Shields CL, Shields JA, et al.: Plaque radiotherapy of uveal melanoma with predominant ciliary body involvement. Arch Ophthalmol 1999, 117:170-177.
32. Shields CL, Naseripour M, Cater J, et al.: Plaque radiotherapy for large posterior uveal melanoma (>8 mm in thickness) in 354 consecutive patients. Ophthalmology 2002, 109:1838-1849. Plaque radiotherapy provided tumor control at 10 years in 87% of patients with selected large posterior uveal melanomas (>8 mm thick) that otherwise would have been managed with enucleation. The large intraocular mass and associated features and radiation complications led to poor visual acuity in most patients. At 10-year follow-up, enucleation was necessary in 34% of patients, and metastasis developed in 55% of patients.
33. Shields CL, Shields JA, Cater J, et al.: Plaque radiotherapy for uveal melanoma. Long-term visual outcome in 1106 patients. Arch Ophthalmol 2000, 118:1219-1228.
34. Shields JA, Augsberger JJ, Brady LW, et al.: Cobalt plaque therapy of posterior uveal melanomas. Ophthalmology 1982, 89:1201-1207.
35. Shields JA, Shields CL, Donoso LA: Management of posterior uveal melanomas. Surv Ophthalmol 1991, 36:161-195.
36. Shields CL, Naseripour M, Shields JA, et al.: Custom-designed plaque radiotherapy for nonresectable iris melanoma in 38 patients: tumor control and ocular complications. Am J Ophthalmol 2003, 135:648-656.
37. Char DH, Kroll SM, Castro JK: Ten-year follow-up of helium ion therapy of uveal melanoma. Am J Ophthalmol 1998, 125:81-89.
38. Gragoudas ES, Goitein M, Verhey L, et al.: Proton beam irradiation. An alternative to enucleation for intraocular melanomas. Ophthalmology 1980, 89:571-581.
39. Gragoudas ES, Lane AM, Munzenrider J, et al.: Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma. Trans Am Ophthalmol Soc 2002, 100:43-48. [discussion 48-49] The 5- and 10-year rates of tumor regrowth after proton therapy were 3% and 4%, respectively. Among the 45 documented recurrences, about one half occurred at the margin, presumably because of treatment planning errors. Recurrence of the tumor was independently related to risk of tumor-related death.
40. Seddon JM, Gragoudas ES, Albert DM, et al.: Comparison of survival rates for patients with uveal melanoma after treatment with proton beam irradiation or enucleation. Am J Ophthalmol 1985, 99:282-290.
41. Gunduz K, Shields CL, Shields JA, et al.: Radiation complications and tumor control after plaque radiotherapy of choroidal melanoma with macular involvement. Am J Ophthalmol 1999, 127:579-588.
42. Shields CL, Cater J, Shields JA, et al.: Combined plaque radiotherapy and transpupillary thermotherapy for choroidal melanoma: tumor control and treatment complications in 270 consecutive patients. Arch Ophthalmol 2002, 120:933-940. Plaque radiotherapy combined with transpupillary thermotherapy provides excellent local tumor control with only 3% recurrence at 5-year follow-up. Treatment-related complications at 5 years included maculopathy in 18% of the patients, papillopathy in 38%, macular retinal vascular obstruction in 18%, vitreous hemorrhage in 18%, rhegmatogenous retinal detachment in 2%, cataract in 6%, and neovascular glaucoma in 7%. Enucleation for radiation complications was necessary in 1%.
43. Shields CL, Shields JA, Karlsson U, et al.: Reasons for enucleation after plaque radiotherapy for posterior uveal melanoma. Ophthalmology 1989, 96:919-924.
44. Shields CL, Shields JA, Karlsson U, et al.: Enucleation following plaque radiotherapy for posterior uveal melanoma. Histopathologic findings. Ophthalmology 1990, 97:1665-1670.
45. Jampol LM, Moy CS, Murray TG, et al.: The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology 2002, 109:2197-2206. The Kaplan-Meier estimate of proportion of patients undergoing enucleation by 5 years was 12.5% and the risk of treatment failure was 10.3%. Treatment failure was the most common reason for enucleation within 3 years of treatment; beyond 3 years, ocular pain was most common.
46. The Collaborative Ocular Melanoma Study Group: The collaborative ocular melanoma study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma II: initial mortality findings. COMS report no. 10. Am J Ophthalmol 1998, 126:779-796. There was no difference in patient survival comparing enucleation with enucleation preceded by external beam radiation.
47. The Collaborative Ocular Melanoma Study Group: Factors predictive of growth and treatment of small choroidal melanoma. COMS report no. 5. Arch Ophthalmol 1997, 115:1537-1544.
48. Benson WE: The COMS: Why was it not stopped sooner? Arch Ophthalmol 2002, 120:672. The Collaborative Ocular Melanoma Study cost $62 million and confirmed previously published information that patient survival after enucleation was similar to that after plaque radiotherapy. There were 200 eyes with 20/20 vision enucleated, and some of these eyes could have been saved if the investigators had reached their final conclusion earlier.
49. Shields JA, Shields CL, Shah P, et al.: Partial lamellar sclerouvectomy for ciliary body and choroidal tumors. Ophthalmology 1991, 98:971-983.
50. Foulds WS, Damato BE: Alternative to enucleation in the management of choroidal melanoma. Aust N Z J Ophthalmol 1986, 14:19-27.
51. Shields JA, Shields CL, DePotter P: Local resection of posterior uveal tumors. In Update on Malignant Ocular Tumors. International Ophthalmology Clinics, Boston. Edited by Shields JA. Little, Brown and Company; 1993:137-142.
52. Wilson RS, Fraunfelder FT: No touch' cryosurgical enucleation: a minimal trauma technique for eyes harboring intraocular malignancy. Ophthalmology 1978, 85:1170-1175.
53. Dutton JJ: Coralline hydroxyapatite as an ocular implant. Ophthalmology 1991, 98:370-377.
54. Shields CL, Shields JA, De Potter P: Hydroxyapatite orbital implant after enucleation. Experience with 100 consecutive cases. Arch Ophthalmol 1992, 110:333-338.
55. Shields CL, Shields JA, DePotter P: Hydroxyapatite orbital implant after enucleation for intraocular tumors. In Update on Malignant Ocular Tumors. International Ophthalmology Clinics, Boston. Edited by Shields JA. Little, Brown and Company; 1993:83-93.
56. Char DH, Phillips TL, Andejeski Y, et al.: Failure of pre-enucleation radiation to decrease uveal melanoma mortality. Am J Ophthalmol 1988, 108:21-26.
57. Shields JA, Shields CL, Suvarnamani C, et al.: Orbital exenteration with eyelid sparing: Indications, technique and results. Ophthalmic Surg 1991, 22:292-297.
58. Shields JA, Shields CL, Demirci H, et al.: Experience with eyelid-sparing orbital exenteration. The 2000 Tullos O. Coston Lecture. Ophthal Plast Reconstr Surg 2001, 17:355-361.
59. Shields JA: Future management of posterior uveal melanoma [Editorial]. Ophthalmic Practice 2001, 19:4.
60. Aoyama T, Mastrangelo MJ, Berd D, et al.: Protracted survival following resection of metastatic uveal melanoma. Cancer 2000, 89:1561-1588.
61. Mavligit GM, Charnsangevej C, Carrasco H, et al.: Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA 1988, 260:974-976.
62. Shields JA: Counseling the patient with a posterior uveal melanoma [Editorial]. Am J Ophthalmol 1988, 106:88-91.
63. Shields JA, Shields CL: The management of posterior uveal melanoma. In Intraocular Tumors. A Text and Atlas. Edited by Shields JA, Shields CL. Philadelphia: Saunders; 1992:191-192.